CD8A and leukemia: Compared with single CAR targeting T cells, CD5/CD7 bispecific CAR-T cells conferred robust protection against the accumulation of single antigen-positive leukemia cells in the peripheral blood of mice (Fig. 6f and Supplementary Fig. 12), and the proportion of CD8+ CAR-T cells in the peripheral blood of mice in the CD5/CD7 bispecific CAR-T treated groups were significantly higher than those in the CD5 CAR-T treated group on day 19 (Fig. 6g).